Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment

Autor: Martijn C. G. J. Brouwers, André Krings, Coen D.A. Stehouwer, Frank de Vries, Johanna H M Driessen, Judith van Dalem, Olaf H. Klungel, Andrea M. Burden
Přispěvatelé: MUMC+: DA KFT Medische Staf (9), Interne Geneeskunde, MUMC+: MA Endocrinologie (9), RS: CARIM - R3.01 - Vascular complications of diabetes and the metabolic syndrome, MUMC+: HVC Pieken Maastricht Studie (9), MUMC+: MA Interne Geneeskunde (3), Epidemiologie, RS: CAPHRI - R5 - Optimising Patient Care, RS: NUTRIM - R3 - Respiratory & Age-related Health, Farmacologie en Toxicologie
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
Diabetes Mellitus
Type 2/drug therapy
type 2 diabetes mellitus
Endocrinology
Diabetes and Metabolism
MONOTHERAPY
Myocardial Infarction
SEVERE HYPOGLYCEMIA
030204 cardiovascular system & hematology
Hypoglycemic Agents/adverse effects
Cohort Studies
0302 clinical medicine
Endocrinology
Risk Factors
Cause of Death
80 and over
Gliclazide
Cause of death
Aged
80 and over
education.field_of_study
OUTCOMES
United Kingdom/epidemiology
Hazard ratio
DEATH
Myocardial Infarction/chemically induced
ASSOCIATION
Middle Aged
sulphonylureas
Type 2/drug therapy
Cardiology
all-cause mortality
Female
USERS
Cohort study
medicine.drug
Adult
medicine.medical_specialty
endocrine system
Adolescent
METFORMIN
Population
acute myocardial infarction
030209 endocrinology & metabolism
EVENTS
03 medical and health sciences
Young Adult
Internal medicine
Internal Medicine
medicine
CARDIOVASCULAR SAFETY
Diabetes Mellitus
Hypoglycemic Agents
Humans
Medical prescription
education
Sulfonylurea Compounds/adverse effects
METAANALYSIS
Aged
business.industry
Proportional hazards model
Survival Analysis
United Kingdom
Confidence interval
Sulfonylurea Compounds
Diabetes Mellitus
Type 2
business
Zdroj: Diabetes Obesity & Metabolism, 20(4), 1056-1060. Wiley
Diabetes, Obesity and Metabolism, 20(4), 1056. Wiley-Blackwell
ISSN: 1463-1326
1462-8902
DOI: 10.1111/dom.13168
Popis: We investigated the association between the current use of individual sulphonylureas and the risk of a first ever acute myocardial infarction (AMI) and all-cause mortality, in a population-based cohort study using primary care data from the Clinical Practice Research Datalink (CPRD) database (2004-2012). New users (N=121,869) with at least one prescription for a non-insulin antidiabetic agent, and aged ≥18 years were included. The first prescription defined start of follow-up. Time-dependent Cox proportional hazards models were used to estimate the risk of a first ever AMI and all-cause mortality associated with the use of individual sulphonylureas, and other non-insulin glucose-lowering drugs. No differences in risk of a first ever AMI (adjusted hazard ratio [HRadj]: 1.02, 95% Confidence Interval [CI]: 0.70-1.50) or all-cause mortality (HRadj: 0.97, 95% CI: 0.80-1.17) were observed comparing gliclazide use with non-gliclazide sulphonylurea use. Similar results were found for each individual sulphonylurea. As evidence is accumulating that gliclazide is no safer than other sulphonylureas, current guidelines suggesting superiority should be carefully evaluated.
Databáze: OpenAIRE
Externí odkaz: